More recent mesothelioma immunotherapy trials such as KEYNOTE-028 (anti-PD-1) and IFCT-1501 MAPS2 (anti-PD-1 monotherapy or combined with anti-CTLA-4) have excluded patients with a peritoneal primary site. The gene discussed is PDCD1; the disease is mesothelioma.